Phase I dose escalation study with sorafenib in combination with sirolimus in patients with solid tumor. - Phase I study with sorafenib and sirolimus

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 18 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•1. Patients with histological or cytological confirmed advanced solid tumor, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a combination of sorafenib and sirolimus (especially metastic RCC, malignant melanoma, HCC, NSCLC, pancreatic cancer, hormone refractory prostate cancer).
•2. Men or women of at least 18 years
•3. Patients who have an ECOG status of 0 or 1
•4. Patients who have a life expectancy of at least 12 weeks
•5. Adequate bone marrow, liver and renal function

•1. History of serious cardiac disease
•2. Active clinically serious bacterial, viral or fungal infections (> grade 2).
•3. Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
•4. Clinically symptomatic brain or meningeal metastasis.

发起方

niversitair Medisch Centrum Sint Radboud